News

Insilico Develops The World’s First Fully AI-Generated Drug

The Abu Dhabi-based company hopes to treat idiopathic pulmonary fibrosis, and has 30 more drugs in the pipeline.

Published

5 months ago

August 15, 2024

Nour Nasir

insilico develops the world's first fully ai-generated drug

Emirates News Agency

In a busy biotech hub in Abu Dhabi’s Masdar City, Insilico Medicine is pushing the frontiers of science. Under the watchful eye of Latvian-born CEO Dr Alex Zhavoronkov, the company has developed an AI-generated drug to treat idiopathic pulmonary fibrosis (IPF) — a deadly disease of the lungs.

“This AI drug is a major milestone for us and the industry as a whole,” Dr. Zhavoronkov explains. “We can use AI to create lifesaving treatments for new diseases using approaches we haven’t yet considered and do so much more rapidly and efficiently”.

insilico ai-generated drug robot

Idiopathic pulmonary fibrosis is characterized by scarring of the lungs and has no known cure. Insilico’s AI drug aims to halt or even reverse the progression of IPF and is currently undergoing Phase 2 clinical trials in the US and China. The success of these trials will pave the way for more in-depth testing, bringing the drug closer to mass market approval.

Insilico’s groundbreaking research was recently published in Nature Biotechnology. It highlights how the company’s AI platform, Pharma.AI, is connecting the dots between fibrosis and aging to drive forward the discovery of a cure.

IPF treatment is just the beginning for Insilico. The company already has a roadmap consisting of over thirty AI-designed drugs, with seven already in clinical patient trials. These include treatments for inflammatory bowel disease, immuno-oncology targets, and even drugs developed using a method that targets a protein in cancers that can kill them without harming healthy cells.

Also Read: Personalized Supplement Company Bioniq Raises $15M In Funds

Dr Zhavoronkov’s ultimate goal is to leverage AI to unravel the complex processes involved in aging. “Our number one priority is to teach AI to understand the basic biology of aging, and I think we’ve succeeded in that process. Now, we need to demonstrate that we can utilize this understanding to cure diseases,” he says.

Insilico Medicine’s AI-driven drugs showcase the massive untapped potential of artificial intelligence in all aspects of healthcare. As the company continues to innovate, its work brings hope to patients around the world and demonstrates that the future of medicine is promising, thanks to the application of the latest technological breakthroughs.

Up Next

WhatsApp Update Will Debut AI Voice Mode With 10 Variants

Don't Miss

Saudi Arabia To Host Sixth Halo Space Test Flight In September

Click to comment

News

Cemplicity Is Bringing Real-Time Patient Insights To The UAE

The advanced healthcare platform offers tools for chronic disease management and improved patient experiences.

Published

2 days ago

January 13, 2025

Nour Nasir

Cemplicity

Cemplicity — a leading health-tech company founded in 2013 — has launched its advanced platform in the UAE, aiming to revolutionize patient care and streamline healthcare operations to improve clinical outcomes.

Designed to analyze patient-reported data in real-time, the platform incorporates Patient-Reported Experience Measures (PREMs) and Patient-Reported Outcome Measures (PROMs) to collect and analyze patient feedback. By transforming the data into actionable insights, healthcare providers will be better equipped to improve quality of care and increase efficiency.

Cemplicity’s technology can even tackle chronic conditions like diabetes, which affects 12.3% of the UAE population. By enabling regular symptom tracking and side-effect monitoring (even when patients are at home) the platform ensures proactive care management, and can also optimize early detection and screening of cancers.

Blaik Wilson, Cemplicity’s CEO, shared: “We are excited to bring Cemplicity to the UAE, a nation committed to healthcare excellence. With the private healthcare sector evolving at an impressive pace, partnering with such forward-thinking providers enables us to transform patient feedback into meaningful insights that enhance patient experiences and improve outcomes”.

Wilson added: “Globally, healthcare produces 30% of the world’s data volume. Aggregating and anonymizing patient-reported data not only uncovers trends and evaluates treatment outcomes but also advances the UAE’s broader ambition to lead in medical research and innovation”.

Also Read: Malak Trabelsi Loeb On Leadership And QIS 2025

With a presence in nine countries and partnerships with major healthcare providers like the UK’s National Health Service (NHS), Cemplicity has already redefined how hospitals and clinics leverage patient feedback. Its tools, known for achieving high survey response rates, help link patient experiences to organizational KPIs and Net Promoter Scores (NPS), enabling measurable improvements in operations, and clinical outcomes, while fostering a culture of continuous improvement.

For the UAE market, the platform has been specially adapted to local needs, offering multilingual support (including Arabic) and seamless integration with tools such as WhatsApp and various hospital management systems.